Advanced searches left 3/3

Treatment Trial - Crossref

Summarized by Plex Scholar
Last Updated: 10 April 2022

* If you want to update the article please login/register

A RANDOMIZED CONTROLL TRIAL TO COMPARE THE EFFICACY OF SACCHAROMYCES BOULARDII, BACILLUS CLAUSII, AND LACTOBACILLUS RHAMNOSUS GG PREPARATION IN THE TREATMENT OF ACUTE DIARRHEA IN CHILDREN

In children with acute diarrhea, Saccharomyces boulardii, Bacillus clausii, and Lactobacillus rhamnosus etamnosus rhamnosus granuloides versus Lactobacillus rhamnosus, B. clausii versus L. rhamnosus GG in acute diarrhea, the aim of the investigation is to determine the pharmacokinetics of Saccharomyr versus Lactobacillus asymptoma rhamnosus versus Lactobacillus s rhamnosus versus Lactobacillus rhamnosus claus rhamnosus claus rhamnosus rham 120 Children were enrolled in the study and randomized to either Group A or Group B, Group C, or Group B. Boulardii was sent by the study's founder and randomized to either Group A or Group B or Group C. Group A received S. clausii, Group B received B. clausii, and Group C received L. rhamnosus GG. Conclusions: In Group C, there was statistically significant increase in consistency observed as compared to Group A of Group B, which is Group A. Conclusions: L. rhamnosus GG's tolerability of S. boulardii, B. clausii, and S. boulardii is a good indicator of diarrhea, while B. clausii and S. boulardii was without adverse effects in our study, but no adverse effects were reported in our analysis.

Source link: https://doi.org/10.22159/ajpcr.2022.v15i4.44199


Evaluation of the safety and efficacy of platelet-rich plasma in the treatment of female patients with chronic telogen effluvium: A randomised, controlled, double-blind, pilot clinical trial

Aims: A pilot study was conducted on chronic telogen effluvium patients to determine the efficacy and safety of platelet-rich plasma and safety of platelet-rich plasma, as well as comparing two different methods of platelet-rich plasma preparation. Methods: The study included 30 female patients with persistent telogen effluvium. The hair pull test, numerical analogue scale, and patient satisfaction survey findings revealed a statistically significant difference between group 1 and group 3 vs. group 3 and group 3 at one and three months after the sessions, with no difference between group 1 and group 2, although there was no difference between group 1 and group 2 at the time. In groups 1 and 2 only, Trichoscopy findings showed a significant rise in hair density and thickness in the frontal region, temporal region, and the vertex. Conclusions: Platelet-rich plasma may be considered a promising therapy for patients with chronic telogen effluvium with an excellent safety record.

Source link: https://doi.org/10.25259/ijdvl_1011_20


Treatment of chronic subdural hematoma with atorvastatin combined with low-dose dexamethasone: phase II randomized proof-of-concept clinical trial

OBJECTIVE The authors tested the possibility that adding dexamethasone to atorvastatin potentiates ATO's effects on chronic subdural hematoma. Patients were randomly assigned to be given ATO 20 mg daily or ATO 20 mg daily plus a DXM regimen. At the 5th week, the patients who were treated with ATO+DXM showed the most noticeable hematoma decrease. In the ATO+DXM and ATO groups, complete recovery of neurological function in 5 weeks was achieved in 83. 3 percent and 32. 1 percent of patients. Patients receiving ATO+DXM for the 5th week had significantly reduced T cells and elevated amounts of regulatory T cells and endothelial progenitor cells in their peripheral blood, as shown by the 5th week. CONCLUSIONS ATO+DXM was more cost-effective than ATO alone in lowering hematoma and improving neurological function in patients with CSDH.

Source link: https://doi.org/10.3171/2019.11.jns192020


Impact of International Subarachnoid Aneurysm Trial results on treatment of ruptured intracranial aneurysms in the United States

Object The use of endovascular therapy for ruptured intracranial aneurysms is expected to change after the publication of the International Subarachnoid Aneurysm Trial in 2002. Using nationally representative results, the authors analyzed the effects of ISAT findings on treatment selection for ruptured intracranial aneurysms and associated in-hospital outcomes. The NIS is the most comprehensive all-payer inpatient care registry in the United States, and it holds data from 986 hospitals approximating a 20% stratified sample of US hospitals. Since the ISAT's publication, there was a significant rise in endovascular care after publication of the ISAT. After the publication of the ISAT, hospital mortality for ruptured intracranial aneurysm admissions decreased from 27 percent to 28 percent. In the post-ISAT period for patients undergoing endovascular therapy, the cost of hospitalization after adjusting for procedures was not significantly higher after the introduction of the ISAT, but hospitalization was higher in the post-ISAT period, but endovascular procedures were higher.

Source link: https://doi.org/10.3171/2010.6.jns091486


Prospective trial of gross-total resection with Gliadel wafers followed by early postoperative Gamma Knife radiosurgery and conformal fractionated radiotherapy as the initial treatment for patients with radiographically suspected, newly diagnosed glioblastoma multiforme

Object This study was designed to determine whether enhanced local control and increased survival can be achieved in patients with glioblastoma multiformes, aggressive resection, Gliadel wafer implantation, Gamma Knife radiosurgery, and fractionated radiotherapy as the initial therapy. Methods: Patients with radiographically suspicious GBMs were tested for participation in a Phase I/II prospective clinical trial. Within two weeks of surgery, Gamma Knife radiosurgery was applied to the resection cavity. The MGMT gene promoter methylation and protein expression was assessed by methylation-specific polymerase chain reaction analysis and immunohistochemical assays for MGMT gene promoter methylation and protein expression to determine the potential effects on the DNA repair mechanism. The 2-year survival rate was 22%, according to the median survival rate for all patients. In 53% of patients, local tumor prevention was successful, and local failure occurred in 47 percent. In 47% of patients, Delayed hydrocephalus necessitant ventriculoperitoneal shunt placement occurred. The combination of vigorous resection, Gliadel wafer implantation, and GKS in comparison to standard fractionated RT in selected patients resulted in increased local control and improved longevity compared to a control group treated with surgery and involved-field RT alone in selected patients. Patients who are undergoing this therapy should be treated judiciously and fully disclosed by an aggressive local tumor therapy.

Source link: https://doi.org/10.3171/jns/2008/109/12/s17


Phase I trial of caudate deep brain stimulation for treatment-resistant tinnitus

OBJECTIVE The aim of this open-label, nonrandomized trial was to determine the effectiveness and safety of bilateral caudate nucleus deep brain stimulation for treatment-resistant tinnitus. Participants were subjected to a stimulation period that ranged from 5 to 13 months, during which the most promising stimulation parameters for tinnitus reduction for each individual were established. To reach the endpoint, these individual optimum stimulation conditions were then applied for 24 weeks of continuous caudate stimulation to reach the endpoint. RESULTS The treatment effect size of caudate DBS for tinnitus was determined by TFI [mean, 23. 3] and THI [30. 8 ] scores, both of which were statistically significant. There were three responders identified by TFI and 4 by THI scores, based on clinically relevant treatment response categorical analysis. In a participant in whom stimulation had been off mode for two months before the event, there was only one severe AE, a suicide attempt unrelated to caudate neuromodulation. CONCLUSIONS BIMA's bilateral nucleus neuromodulation by DBS for acute, refractory tinnitus in this phase I trial showed promising results. Primary and secondary findings showed a highly variable treatment effect size with a 60-60 percent response rate for clinically beneficial health, with no safety issues. The setting of a phase II trial may be able to shorten the duration of the stimulation optimization cycle and improve treatment effect size uniformity.

Source link: https://doi.org/10.3171/2019.4.jns19347


Prophylactic nimodipine treatment for cochlear and facial nerve preservation after vestibular schwannoma surgery: a randomized multicenter Phase III trial

OBJECT A pilot study of prophylactic nimodipine and hydroxyethyl starch treatment demonstrated a beneficial effect on facial and cochlear nerve regeneration after vestibular schwannoma surgery. RESULTS Intent-to-treat research found no statistically significant effects of the therapy on facial nerve function preservation or hearing preservation 12 months after surgery. In both groups, the danger for facial nerve dysfunction deficion was almost identical. In comparison, the risk of postoperative hearing loss in the treatment group was 2 times lower than the control group. Despite the breadth of the confidence intervals, the odds ratios may suggest that but do not show a clinically relevant effect of the safe study medication on the maintenance of cochlear nerve function after VS surgery.

Source link: https://doi.org/10.3171/2015.1.jns142001


Biological effects of acute pravastatin treatment in patients after aneurysmal subarachnoid hemorrhage: a double-blind, placebo-controlled trial

Objective The authors' research has shown that acute pravastatin therapy in patients after aneurysmal subarachnoid hemorrhage, assassination of vaping is able to relieve vaping-related delayed ischemic insufficiencies. Methods Eighty patients with aneurysmal SAH were randomized to receive 40 mg of oral pravastatin or placebo daily for up to 14 days. On Day 3, patients who received pravastatin but not developed vaping asthma had significantly lower baseline LDL cholesterol levels or a less significant decrease in LDL cholesterol, as well as increased plasma fibrinogen and serum C-reactive protein, as compared to those patients without vaping. The reduction in LDL cholesterol levels in the placebo group on Day 3 correlated with the duration of normal cerebral autoregulation on the ipsilateral side of the ruptured aneurysm. Conclusions In addition to functioning via a cholesterol-independent pathway, acute statin therapy following aneurysmal SAH may also function through cholesterol-dependent pathways.

Source link: https://doi.org/10.3171/jns-07/12/1092


Flow diversion in the treatment of aneurysms: a randomized care trial and registry

OBJECTIVE The flow diversion in the Treatment of Intracranial Aneurysm Trial was intended to lead the clinical use of flow diversion, an innovative way to treat intracranial aneurysms, within a care trial and to determine safety and effectiveness. A registry of non-randomized patients treated with flow diversion is included in METHODS FIAT, which was carried out in three Canadian hospitals, that recommended randomized allocation to flow diversion or standard management options, as well as a registry of non-randomized patients treated with flow diversion. For all patients who received flow diversion at any time, the most important safety outcome was death or dependence at 3 months, which will be determined. When compared to 14 of 39 patients randomized to standard therapy, 16 of 38 patients randomly allocated to flow diversion failed to achieve the primary outcome, below expectations of the trial hypothesis: In comparison to 14 of 39 patients randomized to standard therapy, 16 of 38 patients randomly assigned to flow diversion failed to achieve the primary outcome.

Source link: https://doi.org/10.3171/2016.4.jns152662


Prophylactic nimodipine treatment and improvement in hearing outcome after vestibular schwannoma surgery: a combined analysis of a randomized, multicenter, Phase III trial and its pilot study

In vestibular schwannoma surgery, a pilot study and an identically conducted Phase III trial revealed a positive effect of prophylactic nimodipine and hydroxyethyl starch in vestibular schwannoma surgery. From the day before surgery to the 7th postoperative day, the therapy group received parental nimodipine and HES from the day before surgery. When compared to the control group, the intent-to-treat analysis revealed a significant reduction in hearing loss 12 months after surgery. This effect was more apparent after patients were excluded from Class D hearings during preoperative observation. In the treatment group's logistic regression adjusted for tumor size, there was a 4 times reduced risk of hearing loss in the treatment group relative to the control group. With therapy, facial nerve function was not significantly improved. Prophylactic neuroprotective therapy in surgeries in which nerves are at risk seems to be a new and promising concept.

Source link: https://doi.org/10.3171/2016.8.jns16626

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions